<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Selected pharmacologic options for a child with upper gastrointestinal bleeding</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Selected pharmacologic options for a child with upper gastrointestinal bleeding</h1>
<div class="graphic"><div class="figure"><div class="ttl">Selected pharmacologic options for a child with upper gastrointestinal bleeding</div><div class="cntnt"><table cellspacing="0"><colgroup width="20%"></colgroup><colgroup width="60%"></colgroup><colgroup width="20%"></colgroup> <tbody> <tr> <td class="subtitle1"> </td> <td class="subtitle1">Dose</td> <td class="subtitle1">Category</td> </tr> <tr> <td class="subtitle2_left" colspan="3">Acid suppression (IV)*</td> </tr> <tr> <td class="indent1 divider_bottom" rowspan="8">Esomeprazole</td> <td class="sublist1_start"><em>Intermittent dosing:</em></td> <td class="divider_bottom" rowspan="8">PPI</td> </tr> <tr> <td class="indent1">Infants: 0.5 to 1 mg/kg/dose IV once daily</td> </tr> <tr> <td class="indent1">Children 1 to 17 years:</td> </tr> <tr> <td class="indent2">&lt;55 kg: 10 mg IV once or twice daily</td> </tr> <tr> <td class="indent2">≥55 kg: 20 mg IV once or twice daily</td> </tr> <tr> <td class="indent1">Adults: 40 mg IV twice daily</td> </tr> <tr> <td class="sublist1_start"><em>Continuous IV infusion:</em><sup>[1]</sup></td> </tr> <tr class="divider_bottom"> <td class="indent1">1 mg/kg IV bolus (maximum 80 mg), followed by infusion of 0.1 mg/kg/hour (maximum 8 mg/hour)<sup>¶</sup></td> </tr> <tr> <td class="indent1 divider_bottom" rowspan="2">Omeprazole (IV preparation not available in the United States)</td> <td>Children and adolescents:<sup>[2]</sup> 0.5 to 3 mg/kg IV daily in 1 or 2 divided doses (maximum 80 mg daily)</td> <td class="divider_bottom" rowspan="2">PPI</td> </tr> <tr class="divider_bottom"> <td>Adults: 40 mg IV twice daily</td> </tr> <tr> <td class="indent1 divider_bottom" rowspan="7">Pantoprazole</td> <td class="sublist1_start"><em>Intermittent dosing:</em></td> <td class="divider_bottom" rowspan="7">PPI</td> </tr> <tr> <td class="indent1">Children and adolescents:</td> </tr> <tr> <td class="indent2">&lt;40 kg: 0.5 to 1 mg/kg IV once or twice daily</td> </tr> <tr> <td class="indent2">&gt;40 kg: 20 to 40 mg IV once or twice daily</td> </tr> <tr> <td class="indent1">Adults: 40 mg IV twice daily</td> </tr> <tr> <td class="sublist1_start"><em>Continuous IV infusion:</em><sup>[1]</sup></td> </tr> <tr class="divider_bottom"> <td class="indent1">1 mg/kg IV bolus (maximum 80 mg), followed by an infusion of 0.1 mg/kg/hour (maximum 8 mg/hour)<sup>¶</sup></td> </tr> <tr> <td class="subtitle2_left" colspan="3">Acid suppression (oral)<sup>Δ</sup></td> </tr> <tr> <td class="indent1 divider_bottom" rowspan="2">Omeprazole</td> <td>Children and adolescents: 1 to 3 mg/kg daily<sup>[3]</sup> (maximum 80 mg daily) in 1 or 2 divided doses</td> <td class="divider_bottom" rowspan="2">PPI</td> </tr> <tr class="divider_bottom"> <td>Adults: 40 mg twice daily initially, followed by 20 to 40 mg once daily (maintenance dose, once risk of recurrent bleeding is low)</td> </tr> <tr> <td class="indent1 divider_bottom" rowspan="8">Esomeprazole</td> <td class="sublist1_start">Infants 1 month to 1 year (daily):</td> <td class="divider_bottom" rowspan="8">PPI</td> </tr> <tr> <td class="indent1">3 to 5 kg: 2.5 mg</td> </tr> <tr> <td class="indent1">5 to 7.5 kg: 5 mg</td> </tr> <tr> <td class="indent1">7.5 to 12 kg: 10 mg</td> </tr> <tr> <td class="sublist1_start">Children 1 to 11 years (daily):</td> </tr> <tr> <td class="indent1">Weight &lt;20 kg: 10 mg</td> </tr> <tr> <td class="indent1">Weight ≥20 kg: 10 mg or 20 mg<sup>◊</sup></td> </tr> <tr class="divider_bottom"> <td>Children ≥12 years and adults: 40 mg twice daily initially, followed by 20 to 40 mg once daily (as a maintenance dose, once risk of recurrent bleeding is low)</td> </tr> <tr> <td class="indent1 divider_bottom" rowspan="4">Pantoprazole</td> <td class="sublist1_start">Children 5 to 11 years:</td> <td class="divider_bottom" rowspan="4">PPI</td> </tr> <tr> <td class="indent1">Weight 15 to 40 kg: 20 mg once daily</td> </tr> <tr> <td class="indent1">Weight &gt;40 kg: Use adult dose</td> </tr> <tr class="divider_bottom"> <td>Children ≥12 years and adults: 40 mg twice daily initially, followed by 20 to 40 mg once daily (as a maintenance dose, once risk of recurrent bleeding is low)</td> </tr> <tr> <td class="subtitle2_left" colspan="3">Vasoactive agents</td> </tr> <tr> <td class="indent1" rowspan="2">Octreotide</td> <td>Children: 1 to 2 microgram/kg IV bolus (maximum 50 micrograms), followed by 1 to 2 microgram/kg/hour as a continuous IV infusion (maximum 50 micrograms per hour)<sup>[4]</sup>; initial bolus may be repeated once in the first hour if needed</td> <td rowspan="2">Somatostatin analog</td> </tr> <tr> <td>Adults: 50 microgram IV bolus followed by a continuous IV infusion of 50 micrograms per hour; initial bolus may be repeated once in first hour if needed</td> </tr> </tbody></table></div><div class="graphic_lgnd">Pharmacologic options for a child with UGIB. Acid suppression is appropriate for most children with clinically significant UGIB. Children with signs of significant bleeding and active blood loss (eg, hypovolemia, cardiac instability) require immediate stabilization and should be transferred to a pediatric intensive care unit if possible. In general, initial pharmacologic treatment of serious UGIB includes the use of high-dose or continuous IV PPI therapy for acid suppression, which is continued during the period of highest risk for rebleeding (eg, first 3 days). Vasoactive agents may be helpful for selected cases of vascular bleeding (eg, from esophageal varices).</div><div class="graphic_footnotes">IV: intravenous; PPI: proton pump inhibitor; UGIB: upper gastrointestinal bleeding; H2RAs: histamine 2 receptor antagonists.<br/>* IV famotidine (a H2RA) may be used instead of a PPI, but H2RAs are less effective than PPIs in controlling bleeding of peptic ulcers, based on data in adults. For additional information, refer to topic reviews on management of peptic ulcers.<br/>¶ Continuous dosing of IV esomeprazole and pantoprazole is not well established; this protocol has been used and reported by some centers<sup innerhtml="">[1]</sup>.<br/>Δ Optimally, orally administered PPIs are given once daily before the first meal of the day (or if given twice daily, prior to the first meal and the evening meal). Other oral PPIs may be used, including rabeprazole and lansoprazole. For dosing, refer to pediatric drug monographs or topic reviews on gastroesophageal reflux disease in children and adolescents.<br/>◊ In general, the pediatric dose should not exceed the higher end of the adult dose range. On a milligram per kilogram basis, doses of some of the PPIs needed for children are greater than those for adolescents and adults, to obtain a similar degree of acid suppression.</div><div class="graphic_reference">References: 

<ol>
<li>Neidich GA, Cole SR. Gastrointestinal bleeding. Pediatr Rev 2014; 35:243.</li>
<li>Owensby S, Taylor K, Wilkins T. Diagnosis and management of upper gastrointestinal bleeding in children. J Am Board Fam Med 2015; 28:134.</li>
<li>Hassall E, Israel D, Shepherd R, Radke M, Dalväg A, Sköld B, Junghard O, Lundborg P. Omeprazole for treatment of chronic erosive esophagitis in children: a multicenter study of efficacy, safety, tolerability and dose requirements. International Pediatric Omeprazole Study Group. The journal of pediatrics 2000;137(6):800-7</li>
<li>Eroglu Y, Emerick KM, Whitingon PF, et al. Octreotide Therapy for Control of Acute Gastrointestinal Bleeding in Children. J Pediatr Gastroenterol Nutr 2004; 38:41.</li></ol></div><div id="graphicVersion">Graphic 101156 Version 4.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
